Molecular Pharmacology to acquire topical Cox-2 inhibitor for arthritis as part of Australian deal

By Lisa Kerner

Erie, Pa., May 3 - Molecular Pharmacology (USA) Ltd. announced the discovery of a new topically applied COX-2 inhibitor drug candidate, MPL-356, for osteo-arthritis by Molecular Pharmacology Ltd. Australia (MPLA), which MPL-USA is acquiring.

The discovery was verified by MDS Pharma Services, and independent pharmacology testing laboratory, according to a company news release.

MDS' Taiwan laboratory's follow-up replication and dose response study evaluated MPL-356 in the inhibition of human Cyclooxygenase COX-2 in vitro.

MPL-USA said unlike some oral COX-2 inhibitors, topical COX-2 inhibitors may avoid potential systemic side effects while providing anti-arthritic benefits.

MPL-USA is a Los Angeles-based biotechnology company specializing in analgesic and anti-inflammatory products based on the proprietary MPL-TL compound.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.